within Pharmacolibrary.Drugs.N_NervousSystem.N07B_DrugsUsedInAddictiveDisorders.N07BC06_Diamorphine;

model Diamorphine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 2.298333333333333e-05,
    adminDuration = 600,
    adminMass = 5 / 1000000,
    adminCount = 1,
    Vd = 0.00277,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0066,
    k12 = 1.5983333333333333e-05,
    k21 = 1.5983333333333333e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Diamorphine</td></tr><tr><td>ATC code:</td><td>N07BC06</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>5</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>2.77</td><td>L</td></tr>
    <tr><td>clearance:</td><td>19.7</td><td>ml/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Diamorphine, also known as heroin, is a semi-synthetic opioid derived from morphine. It functions as a potent analgesic and is used primarily for the treatment of severe pain, including palliative care and myocardial infarction-related pain. Diamorphine is a controlled substance in most countries but is approved for medical use in some, notably the UK, for pain management and palliative care.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after intravenous administration.</p><h4>References</h4><ol><li><p>Forrest, JA, et al., &amp; Prescott, LF (1982). Clinical pharmacokinetics of paracetamol. <i>Clinical pharmacokinetics</i> 7(2) 93–107. DOI:<a href=\"https://doi.org/10.2165/00003088-198207020-00001\">10.2165/00003088-198207020-00001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7039926/\">https://pubmed.ncbi.nlm.nih.gov/7039926</a></p></li><li><p>Rook, EJ, et al., &amp; Beijnen, JH (2006). Population pharmacokinetics of heroin and its major metabolites. <i>Clinical pharmacokinetics</i> 45(4) 401–417. DOI:<a href=\"https://doi.org/10.2165/00003088-200645040-00005\">10.2165/00003088-200645040-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16584286/\">https://pubmed.ncbi.nlm.nih.gov/16584286</a></p></li><li><p>Kendall, JM, &amp; Latter, VS (2003). Intranasal diamorphine as an alternative to intramuscular morphine: pharmacokinetic and pharmacodynamic aspects. <i>Clinical pharmacokinetics</i> 42(6) 501–513. DOI:<a href=\"https://doi.org/10.2165/00003088-200342060-00001\">10.2165/00003088-200342060-00001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12793836/\">https://pubmed.ncbi.nlm.nih.gov/12793836</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N07BC06 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Diamorphine;
